Atherosclerosis Risk & Advanced Cardiometabolic Panel
The Atherosclerosis Risk & Advanced Cardiometabolic Panel provides an in-depth cardiovascular evaluation by measuring cholesterol, ApoB, Lipoprotein (a), HbA1c, fasting insulin, inflammation, metabolic function, and blood counts. This comprehensive screening helps identify traditional and advanced risk markers linked to arterial plaque development and long-term heart health.
- $980.24
- $198.95
- Save: 79.70%
The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.
Apolipoprotein B
Also known as: CBC, CBC includes Differential and Platelets, CBC/PLT w/DIFF, Complete Blood Count (includes Differential and Platelets)
NOTE: Ulta Lab Tests provides CBC test results from Quest Diagnostics as they are reported. Often, different biomarker results are made available at different time intervals. When reporting the results, Ulta Lab Tests denotes those biomarkers not yet reported as 'pending' for every biomarker the test might report. Only biomarkers Quest Diagnostics observes are incorporated and represented in the final CBC test results provided by Ulta Lab Tests.
Absolute Band Neutrophils (Only Reported If Detected)
Absolute Basophils
Absolute Blasts (Only Reported If Detected)
Absolute Eosinophils
Absolute Lymphocytes
Absolute Metamyelocytes (Only Reported If Detected)
Absolute Monocytes
Absolute Myelocytes (Only Reported If Detected)
Absolute Neutrophils
Absolute Nucleated Rbc (Only Reported If Detected)
Absolute Promyelocytes (Only Reported If Detected)
Band Neutrophils (Only Reported If Detected)
Basophils
Blasts (Only Reported If Detected)
Eosinophils
Hematocrit
Hemoglobin
Lymphocytes
MCH
MCHC
MCV
Metamyelocytes (Only Reported If Detected)
Monocytes
MPV
Myelocytes (Only Reported If Detected)
Neutrophils
Nucleated Rbc (Only Reported If Detected)
Platelet Count
Promyelocytes (Only Reported If Detected)
RDW
Reactive Lymphocytes (Only Reported If Detected)
Red Blood Cell Count
White Blood Cell Count
Also known as: Chem 12, Chemistry Panel, Chemistry Screen, CMP, Complete Metabolic Panel, Comprehensive Metabolic Panel CMP, SMA 12, SMA 20
Albumin
Albumin/Globulin Ratio
Alkaline Phosphatase
Alt
AST
Bilirubin, Total
Bun/Creatinine Ratio
Calcium
Carbon Dioxide
Chloride
Creatinine
Egfr African American
Egfr Non-Afr. American
GFR-AFRICAN AMERICAN
GFR-NON AFRICAN AMERICAN
Globulin
Glucose
Potassium
Protein, Total
Sodium
Urea Nitrogen (Bun)
Also known as: A1c, Glycated Hemoglobin, Glycohemoglobin, Glycosylated Hemoglobin, HA1c, HbA1c, Hemoglobin A1c, Hemoglobin A1c HgbA1C, Hgb A1c
HEMOGLOBIN A1C
Also known as: C-Reactive Protein, Cardio CRP, Cardio hs-CRP, CRP, High Sensitivity CRP, High-sensitivity C-reactive Protein, High-sensitivity CRP, Highly Sensitive CRP, hsCRP, Ultra-sensitive CRP
Hs Crp
Also known as: Insulin (fasting)
Insulin
Also known as: Cholesterol, HDL,Fasting Lipids,Cholesterol, LDL, Fasting Lipids, Lipid Panel (fasting), Lipid Profile (fasting), Lipids
Chol/HDLC Ratio
Cholesterol, Total
HDL Cholesterol
LDL-Cholesterol
Non HDL Cholesterol
Triglycerides
Also known as: Lipoprotein A, Lp (a), Lp(a)
Lipoprotein (A)
The Atherosclerosis Risk & Advanced Cardiometabolic Panel panel contains 8 tests with 65 biomarkers .
The Atherosclerosis Risk & Advanced Cardiometabolic Panel is a comprehensive cardiovascular and metabolic health assessment designed to evaluate traditional and advanced biomarkers associated with atherosclerosis and cardiometabolic disease. By combining lipid markers, inflammatory indicators, glucose regulation tests, insulin levels, and hematologic measurements, this panel provides a multidimensional view of factors that influence arterial plaque development and long-term cardiovascular health.
Atherosclerosis is a progressive condition characterized by the buildup of cholesterol-rich plaque within arterial walls. Its development is influenced by lipid abnormalities, chronic inflammation, insulin resistance, genetic lipoprotein variations, and systemic metabolic imbalance. This panel integrates both foundational and advanced markers—including Apolipoprotein B (ApoB), Lipoprotein (a) [Lp(a)], fasting insulin, and high-sensitivity C-reactive protein (hs-CRP)—to help identify risk patterns that may not be fully captured by a standard cholesterol test alone.
In addition to a Lipid Panel and Hemoglobin A1c, the panel includes a Comprehensive Metabolic Panel (CMP) and Complete Blood Count (CBC) with Differential and Platelets. Together, these tests evaluate cholesterol transport particles, long-term glucose control, organ function, inflammatory activity, and overall hematologic health. This layered approach supports evidence-based cardiovascular risk stratification and cardiometabolic monitoring.
The Atherosclerosis Risk & Advanced Cardiometabolic Panel is commonly used for preventive screening, baseline cardiovascular assessment, or ongoing monitoring of metabolic and lipid-related risk factors. It is particularly valuable for individuals seeking a more detailed understanding of cardiometabolic health, as it evaluates both the quantity and quality of lipoproteins, markers of insulin resistance, and inflammatory contributors to vascular disease.
When and Why Someone Would Order This Panel
Advanced Cardiovascular Risk Assessment
Individuals who want a more detailed evaluation than a standard lipid panel may consider this advanced cardiometabolic screening. Traditional cholesterol measurements provide important information, but advanced markers such as Apolipoprotein B and Lipoprotein (a) offer deeper insight into atherogenic particle burden and inherited cardiovascular risk.
ApoB reflects the total number of potentially plaque-forming lipoprotein particles, while Lp(a) is a genetically influenced lipoprotein associated with increased risk of coronary artery disease. This panel is often used when there is a family history of premature cardiovascular disease or when prior lipid results do not fully explain cardiovascular risk patterns.
Metabolic and Insulin Resistance Evaluation
Insulin resistance plays a central role in metabolic syndrome, type 2 diabetes, and cardiovascular disease. Fasting insulin and Hemoglobin A1c together provide insight into glucose regulation and long-term glycemic exposure. Individuals monitoring metabolic health, weight management programs, or dietary interventions may use this panel to better understand insulin dynamics and cardiometabolic risk.
Inflammation and Vascular Health Monitoring
Chronic low-grade inflammation contributes to plaque progression and vascular instability. hs-CRP is a well-established biomarker associated with cardiovascular risk. Those seeking a broader inflammatory assessment related to arterial health may find this marker particularly informative.
Comprehensive Preventive Screening
This panel may also be ordered as part of a preventive health evaluation for adults seeking a baseline cardiovascular and metabolic profile. Because it includes organ function testing (via CMP) and a CBC with Differential, it offers insight into kidney and liver health, electrolyte balance, and blood cell characteristics that can influence overall cardiovascular well-being.
Ongoing Risk Monitoring
Healthcare providers may use this advanced panel to track changes over time, particularly when lifestyle modifications, nutritional strategies, or physician-directed therapies are being implemented. Periodic monitoring allows for trend analysis and personalized adjustments based on evolving biomarker patterns.
Lipid Panel
The Lipid Panel measures total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. LDL cholesterol is commonly associated with plaque accumulation, while HDL cholesterol supports reverse cholesterol transport. Triglycerides are linked to metabolic health and insulin sensitivity.
Apolipoprotein B (ApoB)
ApoB measures the number of atherogenic lipoprotein particles, including LDL and very-low-density lipoproteins (VLDL). Because each atherogenic particle contains one ApoB molecule, this marker reflects particle count rather than cholesterol content alone, offering enhanced risk insight.
Lipoprotein (a) [Lp(a)]
Lp(a) is a genetically determined lipoprotein that can independently increase cardiovascular risk. Elevated levels are associated with increased likelihood of coronary artery disease and aortic valve disease. Unlike many lipid markers, Lp(a) is largely unaffected by lifestyle changes.
Hemoglobin A1c (HbA1c)
HbA1c reflects average blood glucose levels over approximately three months. It is commonly used to screen for and monitor prediabetes and diabetes, conditions closely linked to atherosclerosis.
Fasting Insulin
Fasting insulin provides insight into insulin production and sensitivity. Elevated fasting insulin may indicate insulin resistance, a key component of metabolic syndrome and cardiometabolic risk.
Comprehensive Metabolic Panel (CMP)
The CMP evaluates kidney function (creatinine, BUN), liver enzymes (ALT, AST, alkaline phosphatase), electrolytes, glucose, and protein levels. Organ health and metabolic balance influence cardiovascular outcomes.
Complete Blood Count (CBC) with Differential and Platelets
The CBC measures red blood cells, white blood cells, hemoglobin, hematocrit, and platelet levels. Abnormalities may provide additional insight into systemic inflammation, oxygen-carrying capacity, and overall hematologic health.
High-Sensitivity C-Reactive Protein (hs-CRP)
hs-CRP detects low levels of inflammation associated with increased cardiovascular risk. Even moderate elevations may reflect vascular inflammation linked to plaque development.
How Patients and Healthcare Providers Use the Results
Comprehensive Risk Stratification
Healthcare providers use this panel to evaluate multiple contributors to atherosclerosis simultaneously. Elevated ApoB, high LDL cholesterol, increased Lp(a), elevated hs-CRP, impaired glucose control, and signs of insulin resistance can collectively signal increased cardiovascular risk.
Identification and Monitoring of Conditions
This panel may support evaluation and monitoring of:
-
Dyslipidemia
-
Metabolic syndrome
-
Insulin resistance
-
Prediabetes and diabetes
-
Chronic systemic inflammation
-
Early kidney or liver dysfunction
Because cardiovascular disease often develops silently, identifying risk patterns before symptoms emerge is an important component of preventive care.
Personalized Health Planning
Results can guide individualized strategies, which may include dietary adjustments, exercise programs, weight management approaches, or physician-directed treatment plans. Advanced markers such as ApoB and Lp(a) may help refine risk assessment beyond traditional cholesterol values alone.
Tracking Trends Over Time
Monitoring changes in LDL cholesterol, ApoB, HbA1c, fasting insulin, and hs-CRP over time provides insight into how lifestyle modifications or medical interventions influence cardiometabolic health. Trend analysis allows for more precise, data-driven care decisions.
The Atherosclerosis Risk & Advanced Cardiometabolic Panel provides a comprehensive and clinically informed evaluation of cardiovascular and metabolic health. By integrating traditional lipid testing with advanced lipoprotein markers, inflammatory indicators, insulin measurements, and organ function assessments, this panel delivers a nuanced understanding of factors that influence atherosclerotic risk.
Cardiovascular disease results from complex interactions among cholesterol transport particles, blood sugar regulation, inflammation, and systemic metabolic balance. This panel reflects that complexity by examining multiple biological pathways rather than relying on a single measurement.
Whether used for baseline screening or ongoing monitoring, the insights gained from this assessment can support informed discussions between patients and healthcare providers. A proactive approach to evaluating cardiometabolic biomarkers can help guide long-term strategies aimed at preserving vascular health and promoting overall well-being.